Isoalloxazine (e.g., Riboflavins, Vitamin B2, Etc.) Patents (Class 514/251)
-
Publication number: 20110117070Abstract: Compositions and methods for the treatment of headaches, such as migraine and cluster headaches, comprising co-administration of a first therapeutic component comprising topiramate and a second therapeutic component comprising a therapeutically effective amount or mixture of one or more therapeutic agents selected from the group consisting of riboflavin, magnesium, coenzyme Q10, petasin, isopetasin, and parthenolide. Also disclosed are methods for increasing the efficacy, and reducing or preventing side effects, of topiramate treatment.Type: ApplicationFiled: July 27, 2010Publication date: May 19, 2011Inventors: Sheena K. Aurora, Curt Hendrix
-
Publication number: 20110110914Abstract: Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.Type: ApplicationFiled: May 11, 2010Publication date: May 12, 2011Inventors: Niven Rajin Narain, John Patrick McCook, Rangaprasad Sarangarajan
-
Publication number: 20110071102Abstract: The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction. Representative afflictions include insomnia, erectile dysfunction, female sexual dysfunction, neuropathic pain, attention deficit disorder, and depression.Type: ApplicationFiled: November 30, 2010Publication date: March 24, 2011Inventors: Jason P. McDevitt, Michael Davis
-
Patent number: 7906514Abstract: An animal model for chronic pain, and in particular lower back pain, is provided. Methods of identifying agents and reducing chronic pain with identified agents such as methotrexate are also provided.Type: GrantFiled: October 28, 1999Date of Patent: March 15, 2011Assignee: Trustees of Dartmouth CollegeInventors: Joyce A. Deleo, James N. Weinstein
-
Publication number: 20110038950Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.Type: ApplicationFiled: July 12, 2010Publication date: February 17, 2011Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
-
Publication number: 20110038940Abstract: A pulverulent composition includes less than 96% in weight, preferably from 10 to 80%, and more preferably from 20% to 70%, of at least a vitamin having a solubility lower than 20 g/L and preferably 1 g/L and more preferably lower than 500 mg/L in aqueous media, the pulverulent composition being stable on storage and having instantaneous dispersion and solubility properties in aqueous solutions.Type: ApplicationFiled: February 6, 2009Publication date: February 17, 2011Applicant: INNOV'IAInventor: Alain Grizeau
-
Publication number: 20110020312Abstract: Methods and formulations for treating metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.Type: ApplicationFiled: May 11, 2010Publication date: January 27, 2011Inventors: Niven Rajin Narain, John Patrick McCook, Rangaprasad Sarangarajan
-
Patent number: 7875612Abstract: A cell population expressing folate receptors is selectively targeted with a non-peptide folic acid analogue. The non-peptide folic acid analogue is conjugated to a diagnostic or therapeutic agent to enable selective delivery of the agent to the targeted cell population.Type: GrantFiled: April 24, 2002Date of Patent: January 25, 2011Assignees: Purdue Research Foundation, Endocyte, Inc.Inventors: Mark A. Green, Chun-Yen Ke, Christopher P. Leamon
-
Publication number: 20110014277Abstract: Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination of the first, second, and third component alters the perceived taste of tobacco smoke.Type: ApplicationFiled: September 29, 2010Publication date: January 20, 2011Inventor: Harlan Clayton Bieley
-
Patent number: 7862838Abstract: A composition and regimen for the treatment of herpes simplex and herpes zoster, primarily through elimination of the pathogenetic conditions by taking into account both pathogenesis and etiology thereof are disclosed. Administration of 1) repeated large dosages of vitamin B2 to eliminate severe vitamin B2 deficiency inherent in herpes simplex and herpes zoster; 2) Strobilanthes cusia and Berberine to ameliorate febrile illness and to clear “hot” condition; 3) Zizyphus semen to relieve psychological stress; and 4) L-lysine to antagonize arginine and alleviate anxiety-all these hereof are for eliminating the pathogenetic conditions. These, in combination with antiviral agents if necessary, constitute the scope and the spirit of the present invention.Type: GrantFiled: August 31, 2009Date of Patent: January 4, 2011Inventor: Qing Si Zeng
-
Publication number: 20100324019Abstract: The invention provides the use of riboflavin in the manufacture of a medicament for the treatment or prophylaxis of elevated blood pressure in a subject homozygous or heterozygous for the MTHFR C677T polymorphism. The invention also provides a pharmaceutical product for the treatment or prophylaxis of elevated blood pressure in a subject homozygous or heterozygous for the MTHFR C677T polymorphism, comprising a pharmaceutically effective amount of an anti-hypertensive agent and riboflavin, and the invention further provides a method of treatment of such a subject comprising the administration of riboflavin.Type: ApplicationFiled: February 22, 2008Publication date: December 23, 2010Inventors: Mary Ward, Helene McNulty, Geraldine Horigan, Sean Strain, John Scott, John Purvis
-
Patent number: 7846442Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: GrantFiled: September 12, 2005Date of Patent: December 7, 2010Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Marc Feldmann, Ravinder N. Maini
-
Patent number: 7838526Abstract: Essential tremor can effectively be treated with high doses of Riboflavin (vitamin B2), either on its own or coupled with one or more other B vitamins and/or coenzyme Q10 (CoQ10). The treatment constitutes a significant improvement over prior treatment methods in that it not only alleviates essential tremor, but results in better performance of the affected body portion and may delay the progression of the disease. The preferred addition of other B vitamins and/or CoQ10 also provides balance to the nutrient energy requirements of a patient's body.Type: GrantFiled: July 20, 2006Date of Patent: November 23, 2010Inventor: Esther Baldinger
-
Patent number: 7838489Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: GrantFiled: October 7, 2008Date of Patent: November 23, 2010Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Marc Feldmann, Ravinder Nath Maini
-
Publication number: 20100285118Abstract: Encapsulated omega-3 fatty acids and/or omega-6 fatty acids and/or esters thereof with a coating comprising isoflavones, as well as a process to make such by coating encapsulated omega-3 fatty acids and/or omega-6 fatty acids and/or esters thereof with a coating comprising isoflavones.Type: ApplicationFiled: October 9, 2008Publication date: November 11, 2010Inventors: Rob Dekker, Henk Husken
-
Publication number: 20100286156Abstract: A collyrium for the treatment of patients suffering from conical cornea contains a riboflavin photosensitizing substance and a surface-active agent to assist penetration of the collyrium into the corneal epithelium. The collyrium does not require removal of the corneal epithelium, with the absence of pain for the patient, who does not need post treatment therapy, and who no longer complains of edema due to the prior art removal of the epithelium, thereby preserving the original corneal transparency.Type: ApplicationFiled: May 6, 2009Publication date: November 11, 2010Inventor: Roberto PINELLI
-
Publication number: 20100278941Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.Type: ApplicationFiled: July 12, 2010Publication date: November 4, 2010Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
-
Publication number: 20100278799Abstract: Provided is a composition for improving the nutritional status, reducing the frequency of fever, and/or increasing the immunocompetence of the elderly. The composition is one for improving the nutritional status, reducing the frequency of fever, and/or increasing the immunocompetence of the elderly and comprises the following components (a) to (e): (a) an antioxidant agent; (b) at least one component selected from the group consisting of vitamin B1, vitamin B2, vitamin B6, niacin, and pantothenic acid; (c) at least one component selected from the group consisting of folic acid and vitamin B12; (d) zinc; and (e) selenium.Type: ApplicationFiled: January 6, 2009Publication date: November 4, 2010Applicant: NUTRI CO., LTD.Inventor: Susumu Kawaguchi
-
Publication number: 20100247505Abstract: Disclosed, is a composition for reducing the levels or level of glucose, malondialdehyde-modified LDL, homocysteine, and/or C-reactive protein in the blood. Specifically disclosed is a composition for reducing the level of at least one substance selected from the group consisting of glucose, malondialdehyde-modified LDL, homocysteine, and C-reactive protein in the blood, which comprises the following components (a) and (b): (a) at least one component selected from the group consisting of vitamin B12, vitamin B6, and folic acid; and (b) at least one component selected from the group consisting of zinc, selenium, and an antioxidant vitamin.Type: ApplicationFiled: October 23, 2008Publication date: September 30, 2010Applicant: NUTRI CO., LTD.Inventor: Susumu Kawaguchi
-
Publication number: 20100239663Abstract: This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/or amino groups. The compound(s) are mixed with a non-toxic carrier that effects sustained release of said compound(s) in the gastrointestinal tract. This invention relates also to food additives and food compositions and packages comprising the composition.Type: ApplicationFiled: May 22, 2007Publication date: September 23, 2010Applicant: BIOHIT OYJInventors: Osmo Suovaniemi, Ville Salaspuro, Martti Marvola, Mikko Salaspuro
-
Publication number: 20100228181Abstract: The present invention relates more specifically to the use of a source of green light for activating L-amino acid oxidase in the presence of at least one substrate of this enzyme in order to stimulate the energy metabolism of the cells of the skin, to stimulate their replacement and thus to improve the appearance of the skin and hair, in particular to prevent and/or treat cutaneous signs of ageing of the skin and hair. The invention also relates to a composition comprising at least one substrate of the enzyme and at least one substrate capable of emitting green light, to a kit comprising a green light device and the composition comprising at least one substrate of the said enzyme and to a cosmetic method employing the compositions or kits according to the invention.Type: ApplicationFiled: July 16, 2008Publication date: September 9, 2010Applicant: L'OREALInventors: Julien Laboureau, Quang Lan Nguyen
-
Publication number: 20100226967Abstract: The invention relates to a method of treating or diagnosing a disease state worsened by progenitor cells. The method utilizes a composition comprising a conjugate or complex of the general formula Ab-X wherein the group Ab comprises a vitamin, or an analog thereof, that binds to progenitor cells, and when the conjugate is being used for treatment of the disease state, the group X comprises an antigen, a cytotoxin, or a compound capable of altering progenitor cell function, and when the conjugate is being used for diagnosing the disease state, the group X comprises a quantifiable marker.Type: ApplicationFiled: May 23, 2007Publication date: September 9, 2010Applicant: PURDUE RESEARCH FOUNDATIONInventors: Philip Stewart Low, Andrew Richard Hilgenbrink
-
Publication number: 20100209504Abstract: A process for producing a granule-containing tablet comprising mixing more than 25 mass % to 89 mass % or less of crystalline cellulose exhibiting a tensile displacement at break of 25 to 80 ?m and a relative fluidity index of 2.15 to 2.80 at a maximum compaction stress of 15 kPa, 10 to 70 mass % of spherical granules, and 20 mass % or less of a disintegrant, and then compressing the obtained mixture.Type: ApplicationFiled: August 26, 2008Publication date: August 19, 2010Applicant: ASAHI KASEI CHEMICALS CORPORATIONInventors: Yoshihito Yaginuma, Naoya Yoshida
-
Patent number: 7776913Abstract: L-carnitine, propionyl L-carnitine and/or acetyl L-carnitine are used to prevent or treat disorders of male andropause caused by ageing or by chemical or surgical castration.Type: GrantFiled: March 14, 2008Date of Patent: August 17, 2010Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Aleardo Koverech, Giulio Biagiotti, Giorgio Cavallini
-
Publication number: 20100203001Abstract: The present invention relates to an improved method of formation of disulfide bridges in substances bearing SH groups, in particular peptides, for example by formation of intramolecular disulfide bridges, in which a heterocyclic compound having at least one nitrogen atom (e.g. caffeine or a caffeine-like substance) is used for catalysis of the reaction. It was found, surprisingly, that addition of the heterocyclic substance increases both the yield and the purity of the product bearing disulfide bridges.Type: ApplicationFiled: December 21, 2007Publication date: August 12, 2010Applicant: APLAGEN GMBHInventors: Karsten Knorr, Marco Emgenbroich, Carsten Büngener
-
Patent number: 7772209Abstract: A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.Type: GrantFiled: July 11, 2007Date of Patent: August 10, 2010Assignee: Eli Lilly and CompanyInventor: Clet Niyikiza
-
Publication number: 20100197626Abstract: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.Type: ApplicationFiled: May 8, 2007Publication date: August 5, 2010Inventors: Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan
-
Publication number: 20100189817Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.Type: ApplicationFiled: April 2, 2008Publication date: July 29, 2010Inventors: Ronald R. Krueger, William J. Dupps, Steven Trokel, Ivey Thornton
-
Patent number: 7758888Abstract: A therapeutic, cosmetic or cosmeceutic composition for topical application, capable of stabilizing an active ingredient and delivering the active ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 micron. The core of each microcapsule includes at least one active ingredient and is encapsulated within a microcapsular shell. The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and is designed to release the active ingredient from the microcapsules following application. The composition is useful in encapsulating active ingredients, such as benzoyl peroxide, that are unstable in other formulation, or are irritating to the skin.Type: GrantFiled: October 23, 2001Date of Patent: July 20, 2010Assignee: Sol-Gel Technologies Ltd.Inventors: Noa Lapidot, Shlomo Magdassi, David Avnir, Claudio Rottman, Orit Gans, Alon Seri-Levy
-
Publication number: 20100179095Abstract: This invention relates to the use of folates for producing a pharmaceutical preparation suitable for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing the inflammation markers C-reactive protein (CRP) and serum amyloid A protein (SAA). The clinical areas of application are all anomalies of the CRP and SAA levels.Type: ApplicationFiled: January 29, 2010Publication date: July 15, 2010Inventors: Thomas MUELLER, Rudolf Moser, Martin Ulmann
-
Publication number: 20100172916Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 9, 2009Publication date: July 8, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Craig Hodulik, Soon Woo
-
Publication number: 20100144746Abstract: A method for restructuring a biological tissue comprising collagen fibrils selected from a venous tissue, a cardiac valvular tissue, a cutaneous or subcutaneous tissue, a tissue of a muscular tendon, a tissue of a muscular fascia or a tissue of a muscular aponeurosis, comprising the following operational steps: a) bringing into contact a biological tissue comprising collagen fibrils with a cross-linking chemical composition able to induce cross-linking of collagen fibrils consequent to activation through electromagnetic radiation; b) activating said cross linking chemical composition through exposure to an electromagnetic radiation; c) cross-linking the collagen fibrils of said biological tissue in order to obtain a restructured biological tissue. The method according to the invention can be applied to recover a venous continence and both a venous and a cardiac valve diameter.Type: ApplicationFiled: December 7, 2009Publication date: June 10, 2010Inventor: Alessandro FRULLINI
-
Publication number: 20100143289Abstract: Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions.Type: ApplicationFiled: December 19, 2007Publication date: June 10, 2010Inventors: Michael Cohen, Jacob Cohen
-
Patent number: 7728134Abstract: Disclosed are hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]Amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide: processes for preparing them and their use as pharmaceutical compositions with antiproliferative activity.Type: GrantFiled: August 4, 2005Date of Patent: June 1, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Guenter Linz, Peter Sieger, Gerd F. Kraemer, Rolf Herter, Matthias Hoffmann, Werner Rall, Rolf Schmid
-
Patent number: 7714011Abstract: A gelled composition formulated to maintain an active ingredient in association with the nasal membrane for an extended period of time is provided. The gelled composition may be formulated as a decongestant or a sinus discomfort relieving agent. The invention further includes a system and method for applying the gelled composition to the nasal membrane.Type: GrantFiled: September 15, 2003Date of Patent: May 11, 2010Assignee: Zicam, LLCInventors: Tim Clarot, Charles Hensley
-
Publication number: 20100099742Abstract: The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular, the cells that can be treated with the cytokine antagonists are drug-resistant cancer cells which fail to undergo apoptosis.Type: ApplicationFiled: November 30, 2009Publication date: April 22, 2010Inventors: Giorgio Stassi, Matilde Todaro
-
Patent number: 7695732Abstract: The invention pertains to a method of treating or preventing pressure ulcers, comprising enterally administering to a subject in need thereof a composition comprising proteins, carbohydrates, fats, arginine or equivalents thereof, ascorbic acid equivalents and ?-tocopherol equivalents, wherein arginine or equivalents thereof is administered in a daily amount of 3-15 g, ascorbic acid equivalents are administered in a daily amount of 180-840 mg and ?-tocopherol equivalents are administered in a daily amount of 50-400 mg.Type: GrantFiled: November 22, 2004Date of Patent: April 13, 2010Assignee: N.V. NutriciaInventors: Maria Anna Verheul-Koot, Chantal Nelleke Kleijer, Robert Johan Joseph Hageman, Roelof Andre Bork, Maud Goethals
-
Patent number: 7691871Abstract: The invention relates to an improved pharmaceutical or dietary composition in form of an aqueous syrup, consisting essentially of (a) vitamins recommended for consumption by children or young adults, (b) a suitable calcium source, (c) at least one dibasic amino acids, (d) taurine, (e) at least one solubilizer, (f) at least one additional agent selected from the group consisting of sweetening agents, flavoring agents, flavor enhancers, preservatives, antioxidants, co-solvents, and (g) water.Type: GrantFiled: August 16, 2004Date of Patent: April 6, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Fabrizio Camponovo, Fabio Danini
-
Publication number: 20100080856Abstract: A composition and a method for administering the composition to a patient in order to accelerate wound healing, particularly postoperative wound healing. The composition, which essentially comprises ornithine ?-ketoglutarate, is water-soluble and formulated for oral administration in single-dose packets. The method for using the composition for promoting wound healing includes the step of administering the composition to a patient preoperatively as well as-postoperatively in accordance with a prescribed protocol. The composition may be customized to include one or more additional agents that are effective for promoting nutritional health and/or treating a particular medical problem. The composition may also be taken daily by athletes to minimize the healing time of closed wounds such as muscle or tendon tears that occur during participation in sports, even when the symptoms of such injury are subclinical.Type: ApplicationFiled: September 26, 2008Publication date: April 1, 2010Inventor: Peter D. Costantino
-
Patent number: 7687473Abstract: The present invention provides a method for increasing the efficacy of antifolates which act via inhibition of dihydrofolate reductase (DHFR). The method comprises the steps of administration of 5-amino-4-imidazolecarboxamide riboside (Z) or its base with the antifolate such that the targeted cells are exposed to both the antifolate and Z simultaneously. This results in increased influx of the antifolate. For MTX, accumulation of the more biologically active polyglutamate forms is also potentiated. This potentiation appears to be mediated by an effect on the RFC.Type: GrantFiled: January 9, 2006Date of Patent: March 30, 2010Assignee: Health Research, Inc.Inventor: John J. McGuire
-
Publication number: 20100035888Abstract: The present invention relates to pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.Type: ApplicationFiled: October 30, 2006Publication date: February 11, 2010Applicant: Bater Healthcare AGInventors: Peter Sandner, Hanna Tinel, Joachim Hütter, Bernd Riedl, Martina Klein
-
Publication number: 20100008923Abstract: The invention relates to pharmaceutical compositions containing inhibitors of histone deacetylase and B vitamins and methods of use thereof, in the treatment of HDAC dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.Type: ApplicationFiled: June 25, 2007Publication date: January 14, 2010Inventor: Michael Shultz
-
Patent number: 7605145Abstract: Formulations for minimizing damage to at least one of cells, organs and systems within the body of a subject afflicted with Diabetes Mellitus. The invention additionally encompasses methods for minimizing said damage which comprise administering to subjects in need thereof a therapeutic amount of a formulation(s) according to the invention.Type: GrantFiled: November 20, 2007Date of Patent: October 20, 2009Assignee: Premier Micronutrient CorporationInventors: Kedar N. Prasad, William C. Cole, Gerald M. Haase
-
Patent number: 7586020Abstract: The present invention provides animal models and methods for the evaluation of maternal treatments that could improve or compromise the epigenetic state, the imprinting, or the DNA methylation and thus the health or disease propensity, of human or other mammalian offspring. In particular, the present invention provides animal models with naturally occurring epigenetic variation for the evaluation of treatments through effects on the epigenetically determined and imprinted characteristics of coat color, coat color pattern, DNA methylation, long terminal repeat (LTR) expression and LTR activity of offspring.Type: GrantFiled: March 29, 2003Date of Patent: September 8, 2009Inventors: Craig Anthony Cooney, George Louis Wolff
-
Patent number: 7572462Abstract: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing during this period or for general application and to enable the person receiving the nutritional supplementation to achieve maximum healing and rapid recovery from a procedure or injury.Type: GrantFiled: March 19, 2007Date of Patent: August 11, 2009Inventor: Edward M. Lane
-
Publication number: 20090192146Abstract: The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions.Type: ApplicationFiled: February 9, 2009Publication date: July 30, 2009Applicant: ACEA BIOSCIENCES, INC.Inventors: Xiao XU, Haoyun An, Xiaobo Wang
-
Patent number: 7560123Abstract: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in subjects undergoing physiologically stressful events, such as, for example and without limitation, pregnancy, lactation or any disease state.Type: GrantFiled: August 12, 2004Date of Patent: July 14, 2009Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles J. Balzer
-
Publication number: 20090176792Abstract: The present invention relates to new dibenzhydrylpiperazine modulators of histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: January 7, 2009Publication date: July 9, 2009Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20090148539Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.Type: ApplicationFiled: July 18, 2008Publication date: June 11, 2009Applicant: Yale UniversityInventors: Jack A. Elias, Zhou Zhu
-
Patent number: RE40849Abstract: Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductan, and reactant. It can be depleted intracellulary either by forming a direct complex with an electrophilic agent (accomplished investigationally by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels.Type: GrantFiled: January 9, 2007Date of Patent: July 14, 2009Assignee: Vit Immune, L.C.Inventors: Robert H. Keller, David W. Kirchenbaum